US equities |
SPCX $168.23 ▲+5.83% NVDA $237.24 ▲+1.41% MU $1,064.56 ▼-0.96% TSLA $378.59 ▲+2.16% MSFT $526.12 ▲+1.66% INTC $116.94 ▼-2.01% SNDK $1,720.36 ▲+0.02% META $745.33 ▲+2.37%
FinancialContent

Aardvark Therapeutics, Inc. - Common Stock (NQ:AARD)

5.130 +0.140 (+2.81%)
Delayed Quote Updated: 10:57 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aardvark Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into Aardvark Therapeutics, Inc. (AARD) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Aardvark Therapeutics, Inc. (AARD) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Encourages Investors of Aardvark Therapeutics, Inc. (NASDAQ: AARD) to Contact the Firm to Learn About Their Legal Rights
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
News headline image
AARD Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Aardvark Therapeutics, Inc.
From Robbins LLP
Via Business Wire
News headline image
Rosen Law Firm Urges Aardvark Therapeutics, Inc. (NASDAQ: AARD) Stockholders to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
AARD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action
From Robbins LLP
Via Business Wire
News headline image
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Unusual volume stocks in Monday's session ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-07-10: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
From Pomerantz LLP
Via GlobeNewswire
Here are the top movers in Friday's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
From Pomerantz LLP
Via GlobeNewswire
News headline image
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
From Pomerantz LLP
Via GlobeNewswire
News headline image
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
From Pomerantz LLP
Via GlobeNewswire
Monday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
< Previous 1 2 3 4 5 Next >